Ocular Surface Disease: Etiologies and Treatment Modalities

This independent educational activity is supported by an unrestricted educational grant from Sun Pharmaceutical Industries.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Differentiate between DED and meibomian gland dysfunction (MGD) and summarize the risk factors for DED and MGD.
• Explain the role of inflammatory processes in these diseases.
• Recognize the signs and symptoms in patients with ocular surface complaints.
• Appraise the differences between traditional and new diagnostic tests for DED and MGD.
• Compare the newest treatments for DED and MGD with first-generation treatments indicated for those conditions.

Accreditation and Designation Statement

Provided by Evolve Medical Education LLC Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Evolve Medical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Evolve is an approved COPE administrator. Supported by State University of New York College of Optometry COPE Approved for 1 credit hour. Course ID: 71293-AS Activity ID: 121126

Participation Method

TO OBTAIN CREDIT To obtain credit for this activity, you must read the activity in its entirety and complete the Pretest/Posttest/Activity Evaluation/Satisfaction Measures Form, which consists of a series of multiple-choice questions.

Course Viewing Requirements

Supported Browsers: Internet Explorer 11 for Windows Edge (recent versions; Chromium-based) for Windows Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements: 4GB+ RAM

Recommended internet speed 5Mbps+

Faculty and Disclosures

Jennifer Loh, MD Founder Loh Ophthalmology Associates Miami, FL   Marc Bloomenstein, OD, FAAO Schwartz Laser Eye Center Director of Optometric Services Scottsdale, AZ   Preeya K. Gupta, MD Associate Professor of Ophthalmology Cornea & Refractive Surgery Duke University Eye Center Durham, NC   Francis Mah, MD Director of Corneal and External Disease Co-Director of Refractive Surgery Scripps Clinic La Jolla, CA   Leslie O’Dell, OD, FAAO Clinical Director Medical Optometry America York, PA   DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests: Jennier Loh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Eyevance, Johnson & Johnson Vision, Kala, Novartis, and Sight Sciences. Grant/Research Support: Sight Sciences. Speaker’s Bureau: Aerie, Kala, Sight Sciences, and Sun Pharmaceutical Industries. Stock/Shareholder: Novabay. Marc Bloomenstein, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bausch + Lomb, Biotissue, Johnson & Johnson Vision, Kala, OcuSoft, Reichert, and Sun Pharmaceutical Industries. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Eyevance, Johnson & Johnson Vision, Kala, Novartis, and Sun Pharmaceutical Industries. Preeya K. Gupta, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Carl Zeiss Meditec, Eyevance, HanAll Biopharma, Johnson & Johnson Vision, Kala, New World Medical, Novartis, Ocular Therapeutix, Oyster Point, ReGen Tree, Sight Sciences, Sun Pharmaceutical Industries, Tear Lab, and Tissue Tech. Francis Mah, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Bausch + Lomb, Eyenovia, Glaukos, iView, Johnson & Johnson Vision, Nevakar, Novartis, Ocular Science, and RxSight. Leslie O’Dell, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Bausch + Lomb, Eye Eco, and Novartis. Speaker’s Bureau: Eye Eco, Sight Sciences, and Sun Pharmaceutical Industries. Share/Stockholder: Eason Labs and EyeGENE. EDITORIAL SUPPORT DISCLOSURES The Evolve staff and planners have no financial relationships with commercial interests. Michelle Dalton, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Cataract & Refractive Surgery Today, Modern Optometry, Sun Pharmaceutical Industries, or Sight Sciences.